Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease
Authors:
- Stefan SchreiberSSStefan Schreiber
- Byung Ik JangBJByung Ik Jang
- Vladimir BorzanVBVladimir Borzan
- Adi LahatALAdi Lahat
- Aldis PukitisAPAldis Pukitis
- Marina OsipenkoMOMarina Osipenko
- Yuriy MostovoyYMYuriy Mostovoy
- Shomron Ben-HorinSBShomron Ben-Horin
- Byong Duk YeBYByong Duk Ye
- Sang Joon LeeSLSang Joon Lee
- Sung Young LeeSLSung Young Lee
- Mi Rim KimMKMi Rim Kim
- 1 May 2018
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-1371-1371